The Founders of Betagenon have over 30 years of experience of internationally competitive research on β-cell function and diabetes. Betagenon AB has access to team of specialists in clinical trials of diabetes and microvascular disease. Betagenon has engaged a MD specialist in internal and renal medicine with Big pharma experience.
PAN-AMPK activator O304: Our clinical focus is on the development O304, a first-in-class PAN-AMPK activator that is orally available and exhibits favorable pre-clinical pharmacology and toxicology profiles. O304 was safe and well tolerated in a phase I and in a 28 day exploratory phase IIa clinical study in patients with type 2 diabetes (T2D) on metformin. In T2D patients, O304 reduced fasting plasma glucose and HOMA-IR. O304 also improved peripheral microvascular perfusion, lowered blood pressure and reduced eGFR by a rapid, stable and reversible hemodynamic effect in T2D patients and in obese non-diabetic subjects. Thus, O304 is ideally suited to target diabetic kidney disease in obese T2D patients, and chronic kidney disease in non-diabetic hyperinsulinemic individuals with central obesity.
Published data from Preclinical and PhaseIIA results with O304:
JCI Insight: https://insight.jci.org/articles/view/99114